Clinical trials: Urticaria Chronic
Healthy Volunteers, Cryopyrin Associated Periodic Syndrome
Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Study With IZD334
This is a first in human (FIH), single-centre, double -blind, randomised, cross-over, SAD followed by a MAD study of IZD334 conducted in healthy adult participants as well as an open-label cohort in adult patients with CAPS.
- Trial name
- NCT04086602
- Testing
- IZD334
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Inflazome UK Ltd
Urticaria
Efficacy and Safety of Rupatadine 10 and 20 Mg in Chronic Idiopathic Urticaria
· To evaluate the efficacy of rupatadine 10 and 20 mg for the treatment of CIU symptoms over four-week treatment period in comparison with placebo.
- Trial name
- NCT00199251
- Testing
- RUPATADINE
- Volunteers
- 300 people
- Sponsor
- J. Uriach and Company
Chronic Urticaria
Study of the Effects of Chinese Herbal Medicine on Chronic Urticaria
Urticaria is a common dermatology disease. Urticaria affects nearly 25% of the population at some time in their lives. Recurrent skin itch, insomnia, daily activities limitation greatly affect the quality of life.
- Trial name
- NCT01715740
- Testing
- Chinese Herbal Medicine (CHM)
- Where
- Taiwan
- Volunteers
- 74 people
- Sponsor
- Chang Gung Memorial Hospital
Chronic Urticaria
Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria
Chronic urticaria can be defined as the occurrence of widespread daily or almost daily wheals for at least 6 weeks, which may be accompanied by angioedema.
- Trial name
- NCT01713725
- Testing
- Omalizumab
- Where
- 4 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Hereditary Periodic Fever Syndromes, Cryopyrin-associated Periodic Syndromes (CAPS)
Ilaris NIS in Korea
This is a study to evaluate safety and effectiveness of Ilaris in adult and pediatric patients receiving the drug in a clinical setting for any of the following indications, Hereditary Periodic Fever Syndromes…
- Conditions
- Hereditary Periodic Fever Syndromes, Cryopyrin-associated Periodic Syndromes (CAPS), Colchicine Resistance Familial Mediterranean Fever (crFMF), TNF Receptor Associated Periodic Syndrome (TRAPS)
- Trial name
- REASSURE (NCT06838143)
- Testing
- Ilaris
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Urticaria, Vitamin D Deficiency
A Trial to Evaluate the Effect of Vitamin D Supplementation in Patients With Chronic Urticaria
This study will be an assessor-blind, randomized controlled trial in patients with CSU. The investigators will compared Vit D level in patients with Chronic spontaneous urticaria (CSU) and controls.
- Trial name
- NCT03991845
- Testing
- Vit D
- Where
- India
- Volunteers
- 262 people, healthy volunteers welcome
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Chronic Spontaneous Urticaria
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria
The purpose of this study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation…
- Trial name
- EMBARQ-CSU1 (NCT06445023)
- Testing
- barzolvolimab
- Where
- 235 sites in United States, Argentina and 19 more
- Volunteers
- 963 people
- Sponsor
- Celldex Therapeutics
Chronic Spotaneous Urticaria, Idiopathic Non Histaminergic Angioderma, Hereditary Angioedema With C1 Inhibitor Deficiency
The Role of the Coagulation Pathways in Recurrent Angioedema
Previous studies reported infraclinical modifications of the homeostasis in chronic urticaria, recurrent idiopathic angioedema and hereditary angioedema.
- Trial name
- Angiocoag (NCT02892682)
- Testing
- BLOOD TEST
- Where
- France
- Volunteers
- 96 people
- Sponsor
- University Hospital, Montpellier
Chronic Idiopathic Urticaria
Efficacy and Safety of Omalizumab in Chronic Idiopathic Urticaria
The study is designed to assess the efficacy and safety of monthly injections of Omalizumab 150 mg for 3 consecutive months, in patients with chronic idiopathic urticaria, unresponsive to convetional therapy by antihistamins or…
- Trial name
- NCT02166151
- Testing
- Omalizimab
- Where
- Israel
- Volunteers
- 20 people
- Sponsor
- Rabin Medical Center
Chronic Spontaneous Urticaria (CSU)
A Prospective, Single-centre, Observational Cohort Study on the Efficacy and Safety of Bacterial Lysate (OM-85) in Combination With Antihistamines for the Treatment of Chronic Spontaneous Urticaria (CSU)
A Prospective Clinical Study on the Efficacy and Safety of Bacterial Lysate (OM-85) Combined with Antihistamines in the Treatment of Chronic Spontaneous Urticaria (CSU): A Single-Centre, Observational, Cohort Study
- Trial name
- NCT07557888
- Where
- China
- Volunteers
- 132 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Chronic Spontaneous Urticaria
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Spontaneous Urticaria.
This is a randomized, double-blind, placebo-controlled phase 1/2 clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HS-10561 capsule in healthy Chinese adults and patients with…
- Trial name
- NCT06864507
- Testing
- HS-10561
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Chronic Spontaneous Urticaria
OPTIMA: Efficacy of Optimized Re-treatment and Step-up Therapy With Omalizumab in Chronic Spontaneous Urticaria (CSU) Patients
This trial assessed the efficacy of optimized re-treatment therapy with omalizumab (150mg or 300mg) after relapse, in participants with Chronic Spontaneous Urticaria who were clinically well-controlled following their first…
- Trial name
- OPTIMA (NCT02161562)
- Testing
- omalizumab
- Where
- 35 sites in Argentina, Brazil and 6 more
- Volunteers
- 314 people
- Sponsor
- Novartis Pharmaceuticals
Urticaria
Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria
The objective of the study is to evaluate the efficacy and tolerability of Bilastine 20 mg Q.D., compared to Levocetirizine 5 mg Q.D. and placebo for the treatment of Chronic Idiopathic Urticaria.
- Trial name
- NCT00421109
- Testing
- Bilastine, Levocetirizine
- Where
- 50 sites in Argentina, Belgium and 5 more
- Volunteers
- 522 people
- Sponsor
- Faes Farma, S.A.
Chronic Spontaneous Urticaria
A Trial of HRS-3095 in Healthy Volunteers
The purpose of this study is to assess safety, PK, Pharmacodynamic profile of a single dose of HRS-3095 in healthy participants
- Trial name
- NCT07686484
- Testing
- HRS-3095
- Where
- Australia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Atridia Pty Ltd.
Chronic Spontaneous Urticaria
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
This is a placebo and active-controlled phase 2b dose-finding study to evaluate efficacy and safety of QGE031 monthly subcutaneous injections as add-on therapy in patients with Chronic Spontaneous Urticaria.
- Trial name
- NCT02477332
- Testing
- QGE031, Omalizumab
- Where
- 82 sites in United States, Australia and 8 more
- Volunteers
- 382 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Inducible Urticaria
Study of Efficacy and Safety of Ligelizumab in Adolescents and Adults With Chronic Inducible Urticaria Who Remain Symptomatic Despite Treatment With H1- Antihistamines
This was a placebo controlled, phase 3 study designed to evaluate the efficacy and safety of ligelizumab in participants with chronic inducible urticaria who are inadequately controlled with H1-antihistamines
- Trial name
- PEARL-PROVOKE (NCT05024058)
- Testing
- Ligelizumab
- Where
- 24 sites in United States, Australia and 7 more
- Volunteers
- 39 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Idiopathic Urticaria
A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment
The study is a global Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of omalizumab administered subcutaneously as an add-on therapy for the treatment…
- Trial name
- NCT01287117
- Testing
- Omalizumab
- Where
- 66 sites in United States, Denmark and 6 more
- Volunteers
- 319 people
- Sponsor
- Genentech, Inc.
Cryopyrin Associated Periodic Syndrome, Familial Cold Urticaria
Circadian Rhythm Deregulation in Patients With CAPS
Circadian rhythms are characterized by the physiology's adaptation to the alternation of day and night, enabling to adapt to the environment. These rhythms are generated by a molecular clock within each cell.
- Conditions
- Cryopyrin Associated Periodic Syndrome, Familial Cold Urticaria, Muckle-Wells Syndrome, CINCA Syndrome
- Trial name
- ICARUS (NCT06544018)
- Testing
- Genetic analysis of NLRP3, Circadian rhythm measurement, Saliva sampling
- Where
- 6 sites in France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Chronic Spontaneous Urticaria
To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria
This study is a multicenter, randomized, double-blind, positive parallel controlled phase III clinical trial to compare efficacy, immunogenicity, pharmacokinetics, pharmacodynamics and safety of omalizumab α(CMAB007) and Xolair®…
- Trial name
- NCT06365879
- Testing
- CMAB007, Xolair
- Where
- China
- Volunteers
- 392 people
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome
Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase
To date there are no approved effective therapies for the treatment of cryopyrin-associated periodic syndromes (CAPS) including Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS), or Neonatal Onset…
- Conditions
- Cryopyrin-associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease
- Trial name
- NCT00991146
- Testing
- canakinumab
- Where
- 3 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Novartis Pharmaceuticals